Epidermal growth factor augments postpneumonectomy lung growth  by Kaza, Aditya K. et al.
O ne of the problems in lung transplantation is thelack of potential growth in the transplanted organs.
This problem may be more apparent in pediatric
patients and in patients receiving reduced-size allo-
grafts. Traditionally, it was thought that adult lungs had
reached a growth plateau, believed to be irreversible.
Our laboratory recently showed that adult lungs exhibit
growth when they are transplanted into immature recip-
ients.1 This finding led to the hypothesis that there may
be specific growth factors that could induce growth in
adult lung tissue similar to that seen in the perinatal
state. After pneumonectomy, the remaining lung
exhibits rapid and restorative growth.2,3 However, the
stimuli, mechanisms, and regulation of this growth
process remain unclear. Various growth factors have
been implicated in the regulation of the different com-
Objective: Epidermal growth factor has been shown to play an important role
in prenatal and postnatal lung development, but little is known about its
effects on adult lung growth. We hypothesized that postpneumonectomy
compensatory lung growth can be augmented by the administration of epi-
dermal growth factor. 
Methods: Adult Sprague-Dawley rats were divided into 3 groups. Sham left
thoracotomy was performed in the first group (group C), left pneumonecto-
my in the second group (group P), and left pneumonectomy with adminis-
tration of epidermal growth factor (0.2 µg/g body weight intraperitoneally, at
72-hour intervals) in the third group (group E). The right lung growth was
studied in each group 1, 3, 5, 10, and 21 days after the operation. Lung
weights (in grams) and volumes (in milliliters) were expressed as a ratio to
the total body weight (in kilograms) (lung weight and volume indices).
Epidermal growth factor receptor was quantitated by using Western blotting.
Results: Using analysis of variance and contrast analysis, we noted a signif-
icant increase in lung weight index in group E versus group P rats at 3 days
(3.08 vs 2.75; P = .034) and 21 days (4.62 vs 3.61; P = .006). Lung volume
index was significantly increased in group E versus group P rats at 5 (16.98
vs 15.09), 10 (24.48 vs 18.81), and 21 (28.54 vs 21.01) days (P < .001).
Epidermal growth factor receptor was noted to be up-regulated in the lungs
of animals that received exogenous epidermal growth factor. 
Conclusions: This study demonstrates that administration of exogenous epi-
dermal growth factor has a significant effect on postpneumonectomy lung
growth. This process may be mediated by an up-regulation of growth factor
receptor expression in the contralateral lung.  (J Thorac Cardiovasc Surg
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ponents of lung growth and maturation. However, the
role of growth factors in regulating compensatory
growth after pneumonectomy or lobectomy is
unknown. We chose to use a postpneumonectomy lung
growth model in the rat to study lung growth because
of the rapid, consistent, and well-characterized lung
growth in this animal.
Epidermal growth factor (EGF) has been shown to
play an important role in prenatal and postnatal lung
development. EGF is a bioactive peptide that modu-
lates epithelial maturation and regeneration, and the
lung has been shown to harbor receptors for EGF on
various cell types such as ciliated cells and alveolar
cells. Raaberg and associates4 demonstrated EGF
immunoreactivity in type II pneumocytes and in the
cells of the bronchi and bronchioles from a few days
before birth and throughout life. In addition, Ruocco
and colleagues5 postulated that EGF, in addition to
being mitogenic, functions in a paracrine fashion to
help in epithelial maturation of the lung tissue. Most
experimental data correlating EGF and lung growth
have been generated from the study of fetal specimens.
For example, Catterton and coworkers6 showed that
EGF injected into a rabbit fetus caused accelerated
maturation of the lung.
In this study, we investigated the role of exogenously
administered EGF on postpneumonectomy lung
growth. The lung growth was then analyzed by using
lung weight and volume to determine whether EGF
plays a significant role in the compensatory growth of
a mature lung. Western blot analysis and morphometric
techniques were used in an attempt to understand this
response at the cellular level.
Material and methods
Adult male Sprague-Dawley rats were used for all exper-
iments. Animal acquisition was under the supervision of
the Department of Comparative Medicine and a licensed
veterinarian. The facilities used for animal care are accred-
ited by the American Association for Accreditation of
Laboratory Animal Care. The facility is approved by the
Institutional Animal Care and Use Committee. All animals
received humane care in compliance with the “Principles of
Laboratory Animal Care” formulated by the National
Society for Medical Research and the “Guide for the Care
and Use of Laboratory Animals” prepared by the Institute
of Laboratory Animal Resources, National Research
Council, and published by the National Academy Press,
revised 1996.
Operative model. Rats were divided into 3 major groups:
C, P, and E. Each group was then subdivided into 5 groups on
the basis of postoperative survival time (1, 3, 5, 10, and 21
days). We began with 8 animals in each subgroup to allow for
an adequate number of tissue samples for molecular and mor-
phometric analysis. All animals were anesthetized with a
combination of ketamine and xylazine injected intraperi-
toneally followed by endotracheal intubation with a 16F
catheter. Their lungs were then ventilated with room air by
using a pressure regulated rodent ventilator (Kent Scientific,
Litchfield, Conn). The rats were then placed in the right lat-
eral decubitus position and shaved and prepped in a sterile
fashion. 
Animals in group C underwent a sham thoracotomy on
the left side. Animals in group P underwent a left pneu-
monectomy. Animals in group E underwent a left pneu-
monectomy with the administration of exogenous EGF (0.2
µg/g, dosed intraperitoneally every 72 hours, R&D
Systems, Minneapolis, Minn). After the sham left thoraco-
tomy (group C), the chest was closed after an expiratory
sigh, with use of 3-0 silk sutures, and the skin was closed
with surgical staples. Animals in groups P and E underwent
a posterolateral thoracotomy, and the left lung was freed
from the inferior pulmonary ligament. The lung was then
delivered into the surgical wound, the hilum was tied with
a 4-0 silk ligature, and the lung was excised. The chest wall
was closed as described above. The animals were allowed
to recover from the operation and their lungs were extubat-
ed after spontaneous respirations began. The animals then
received analgesia in the form of buprenorphine, injected
intramuscularly every 12 hours for the first 24 hours. The
animals were allowed to feed freely and were kept in a con-
trolled environment. After the designated interval, the ani-
mals were anesthetized and intubated via a tracheostomy.
Exposure of the thoracic organs was obtained by a bilater-
al anterior sterno thoracotomy. The animals were rapidly
killed by vena caval division. The right lung in half of the
animals was removed, patted dry, weighed, snap frozen in
liquid nitrogen, and stored at –80°C for molecular analy-
ses. The remaining animals received intratracheal instilla-
tion of 2% glutaraldehyde to a pressure of 25 cm H2O. The
right lung was then removed with the fixative in place and
ligated at the hilum. Lung volume was obtained by the vol-
ume displacement technique as described by Scherle.7 The
lung was then embedded in paraffin, and 5-µm sections
were stained with hematoxylin and eosin for morphometric
analysis. 
Morphometry. Lung morphometry was carried out with
the point counting technique described by Gil8 and the 3-level
sampling technique described by Davies9 and Wandel,
Berger, and Burri.10 The volumes of the various respiratory
regions were determined by using a 42-point test reticule (lat-
tice with 85-µm grid lines) attached to a Nikon Eclipse E400
microscope. This technique is briefly described below. The
first level of analysis, usually performed under gross inspec-
tion, was not performed, because of the small size of the rat
lung and the lack of accurate differentiation at the gross level;
thus, all the morphometric measurements need to be inter-
preted as relative values. The second level of analysis was
performed at 50× magnification. The number of lattice points
that fell on intra-acinar air space and their intervening tissue
is designated as Pr. Points that correspond with extra-acinar
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airways and vessels less than 0.5 mm in diameter were
ignored. The volume of the respiratory region (Vvr) was cal-
culated by using the following equation:
Vvr = (Pr/42) · 100
The third level of analysis was performed at 200× magnifi-
cation. The number of lattice points that overlap the respira-
tory airspaces was designated as Pra. The volume of the res-
piratory airspace (Vra) was calculated by using the following
equation:
Vra = (Pra/42) · 100
The next level of analysis was also performed at 200× mag-
nification. The number of test lines intercepting the airspace-
epithelial interface was designated as Is. The alveolar surface
density (Sv), a linear measurement that expresses the number
of alveoli per centimeter, was then determined by using the
following equation:
Sv = 2/d · (Is/Pp)
where d = length of the test grid line (85 µm) and Pp = total
number of test points on the lung parenchyma = 42.
The relative values of the various respiratory compartments
in the lung were then calculated as follows:
The total volume of respiratory region (TVvr) = Vvr · VL,
is a measure of the total volume of alveoli and the interven-
ing gas exchange tissue in the lung.
The total volume of the respiratory airspace (TVvra) =
Vvra · Vvr · VL, is a measure of the volume of alveoli in the
lung, where VL = total volume of the lung.
Western analysis. Total lung protein (120 µg) was frac-
tionated on a 7.5% (weight per volume) sodium dodecyl sul-
fate polyacrylamide gel and transferred to nitrocellulose with
use of an electrophoretic transfer cell (BioRad, Hercules,
Calif). The blot was blocked and incubated with 1-µg/mL
primary rabbit-polyclonal anti-EGF-receptor (EGFR) anti-
body (Santa Cruz Biotechnology, Santa Cruz, Calif) for 1 to
3 hours at room temperature, followed by washing with 50
mmol/L Tris HCl pH 7.4, 150 mmol/L NaCl, 0.1% Tween.
The blot was then incubated for 1 hour with mouse-mono-
clonal anti-rabbit IgG secondary antibody coupled to horse-
radish peroxidase (1:3000, Biorad) and washed as before.
Protein bands were visualized by chemiluminescence (ECL;
Amersham, Piscataway, NJ) and quantitated by means of
computerized densitometry (Alpha Innotech Corp, San
Leandro, Calif). 
Statistical methods. Measurements are reported as the
mean ± SD. One-way analysis of variance (ANOVA) and
contrast analysis were used to determine whether a difference
existed between study groups. The Bonferroni adjustment
(multiple comparison test) was used when appropriate.
Results
The right lung weights and volumes were analyzed
among the 3 groups (C, P, E) at the various time inter-
vals (1, 3, 5, 10, and 21 days). The lung weight (in
grams) and volume (in cubic centimeters) were
expressed as a ratio to the total body weight of the ani-
mal (in kilograms), which are designated as the lung
weight and volume index. Comparison of lung weight
index is shown in Fig 1. At 1 day there was no differ-
ence between the various groups. At 3 days there were
significant differences for C vs P and E (P = .004). At
5 days there were significant differences for C vs P and
E (P = .020). At 10 days we noted significant differ-
ences between C vs P and E (P = .001). At 21 days
there were significant differences for C and P vs E (P =
.006). Both the EGF treatment group and the pneu-
monectomy group had significantly higher lung weight
index at 3, 5, 10, and 21 days when compared with the
Fig 1. Lung weight index. Lung weight index (in grams per kilogram body weight) plotted at the various postop-
erative time intervals. Increase in lung weight index is noted in rats that underwent pneumonectomy with the
administration of exogenous EGF (E) compared with pneumonectomy (P) and sham thoracotomy animals (C) at 3
and 21 days (P < .05). *P < .05 vs P, C.
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sham group. Using contrast analysis, we tested our
hypothesis for any difference between groups P and E
at the various time points. We noted significant increase
in lung weight index at 3 days (P = .034) and 21 days 
(P = .014) in group E compared with group P.
The results of the lung volume index are shown in
Fig 2. At 1 day there were no differences between the
groups (P = .491, NS). At 3 days there was a signifi-
cant increase in C compared with P (P = .04). At 5
days there were significant increases in E vs P and C
and in P vs C (P < .001). At 10 days there were sig-
nificant increases noted in group E vs P and C and in
P vs C (P < .001). Similarly, at 21 days there were
significant increases noted in group E vs P and C and
P vs C (P < .001). We noted that the EGF treatment
group and the pneumonectomy group had a signifi-
cantly higher lung volume index at 3, 5, 10, and 21
days when compared with the sham group. Contrast
analysis done to test the validity of our hypothesis
revealed a significant increase in lung volume index
in group E compared with group P at 5, 10, and 21
days (P < .001).
Morphometric analysis was performed on the lung
tissue from the 3 groups at 10 and 21 days because
maximal variability in lung volume was noted at these
time points (Table I). The surface density of alveoli
(Sv) was found to be similar among all groups at both
time intervals. The volume of the respiratory region
(TVvr) was increased in group E at the 10-day (6.78 ±
1.3 mL; P < .001 vs P10 and C10) and 21-day (9.72 ±
1.5 mL; P < .001 vs P21 and C21) intervals. The vol-
ume of the respiratory airspace (TVvra) in the lung was
elevated in group E at the 21-day interval (6.74 ± 2.7
mL; P = .003 vs P21 and C21).
Western analysis was performed for the detection of
EGFR in the lung tissue from the 3 groups at 1-, 3-, and
5-day intervals. We also used lung tissue from unoper-
ated age-matched animals (N) for internal control. The
Fig 2. Lung volume index. Lung volume index (in milliliters per kilogram of body weight) plotted at the various
postoperative time intervals. Increase in lung volume index is noted in rats that underwent pneumonectomy with
the administration of exogenous EGF (E) compared with pneumonectomy (P) and sham thoracotomy animals (C)
at 5, 10, and 21 day intervals (P < .001). *P < .001 vs P, C.
Table I. Results of morphometric analysis
Group Sv (cm–1) TVvr (mL) TVvra (mL)
C10 286.3 ± 62.6 3.87 ± 0.3 2.39 ± 0.8 
P10 288.2 ± 26.9 5.32 ± 1.0 3.41 ± 0.9
E10 280.1 ± 47.5* 6.78 ± 1.3† 4.59 ± 1.7‡
C21 324.9 ± 75.2 5.56 ± 0.4 3.39 ± 1.1
P21 298.8 ± 46.6 7.19 ± 0.3 4.40 ± 1.4
E21 265.8 ± 30.1§ 9.72 ± 1.5 6.74 ± 2.7¶
Sv, Alveolar surface density; TVvr, total volume of respiratory regions; TVvra, total volume of respiratory airspaces.
*P = .932 vs C10, P10.
†P < .001 vs C10, P10.
‡P = .003 vs C10. 
§P = .087 vs C21. 
P < .001 vs C21, P21.
¶P = .003 vs C21, P21.
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results are shown in Fig 3. The Western blotting was
performed on tissue from 1, 3, and 5 days because we
thought that molecular events would be more evident at
these earlier time points. These earlier time points were
also thought to represent the periods of rapid growth.
At 1 day we noted an up-regulation in EGFR expres-
sion in group E vs N, C1, and P1 (3.47 ± 0.49; P <
.001). Similarly, at 5 days we noted a significant upreg-
ulation of EGFR in E5 vs N, C5, and P5 (2.22 ± 0.35;
P < .001). 
Discussion
Growth of a mature lung has been observed after both
lung injury and pneumonectomy. After lung epithelial
injury, type II cells proliferate and eventually line the
alveolar septa as rows of columnar cells. During the
course of healing, these type II cells differentiate into
type I cells to allow the reconstitution of normal alveo-
lar parenchymal architecture. Type II cell proliferation
is the critical step in the structural and functional
restoration after lung epithelial injury.11 Pneumo-
nectomy and lobectomy initiate compensatory growth
that results in restoration of lung volume, compliance,
and mass to the remaining lung. Restoration of whole
lung levels of protein, RNA, DNA, collagen, and
elastin, along with essentially normal lung cell popula-
tions, also occurs.2 Lung expansion, or stretch, has a
definite role in the initiation of compensatory growth.
Although there is no dispute that the remaining tissue
undergoes growth after pneumonectomy, the nature
and extent of the growth are not fully understood.
Whether compensatory growth of the lung involves for-
mation of new alveoli is controversial, and several bio-
chemical studies indicate that lung mass is restored by
hyperplastic growth of the remaining tissue rather than
by hypertrophy of individual cells.2 This is exemplified
in the rat within the first day after pneumonectomy by
pleural, mesothelial, and peripheral alveolar cell divi-
sion, and 6 to 7 days later mitoses are found through-
out the lung.12 There is evidence that type II cells play
a role in compensatory growth since type II cells iso-
lated from the lungs of pneumonectomized rats exhib-
ited metabolic changes typical of accelerated cell
growth.13
Utilizing the rodent model of postpneumonectomy
lung growth, we were able to demonstrate that the
administration of exogenous EGF had a significant
effect on the growth of the contralateral lung. The
effect of EGF in augmenting lung growth is illustrated
by an increase in the lung weight index noted at 3 and
21 days. Wet/dry ratios were not determined because it
has been shown in the literature that compensatory
growth response of the lung after pneumonectomy is
not caused by an accumulation of blood or fluid but by
an increase in lung tissue.14 This is further supported
by the fact that the lung volume index was significant-
ly elevated at 5, 10, and 21 days in animals that
received exogenous EGF.
Morphometric analysis of lung tissue revealed an
increase in the volume of the respiratory regions and
respiratory airspace in animals that received exogenous
EGF. However, the alveolar surface density remained
Fig 3. Western blot analysis for epidermal growth factor receptor (EGFR). The Western blot is shown on top and
the computerized densitometry shown at the bottom. The EGFR expression in the EGF treatment group at 1 day
(E1) was significantly higher when compared with unoperated normals (N), sham thoracotomy (C1), and
pneuomonectomy (P1) animals (P < .001). Similarly, EGFR expression in E5 was significantly higher than N, C5,
and P5 (P < .001).
unchanged, which indicates that the microscopic archi-
tecture of the alveoli was preserved. This evidence of
increased volume of respiratory region and respiratory
airspace when combined with the increased total lung
volume noted by volumetry indicates that EGF has a
substantial role in regulating the replication and growth
of the various components of the lung parenchyma.
These data, combined with the constant nature of the
surface density of alveoli, indicate that EGF acts in a
bimodal fashion in the lung. Initially, there must be a
hyperplastic phase, mediated by the growth factor
receptor, and a secondary process during which the
replicated alveolar units are restored to their original
size by a hypertrophic response.
Western blot analysis of the lung tissue for EGFR
revealed that its expression was up-regulated in rats
that received exogenous EGF at 1 and 5 days. This
could represent an autoregulatory process, whereby the
exogenous growth factor induces the expression of its
receptor. This up-regulation of EGFR could account for
the effect of exogenously administered EGF on lung
growth. EGFR has been shown to be vital to the devel-
opment of the lung; EGFR-deficient mice were shown
to have evidence of lung immaturity as a result of
impaired branching and deficient alveolization and
septation.15 The regulation of EGFR has been shown to
be important for the timing of mesenchymal-epithelial
cell communication, which is necessary for surfactant
synthesis.16
We believe this is the first evidence that administra-
tion of exogenous growth factor can influence the
growth of adult lung tissue. This study illustrates the
role of a single growth factor on lung growth. Further
investigations are needed to determine the various sig-
nals and growth factors that can initiate growth in adult
lung tissue. The next step is to understand the role of
EGF in experimental transplantation and to determine
whether it has a role in augmenting the growth of trans-
planted lungs. The clinical applications of understand-
ing lung growth are manifold. It could help us modu-
late the growth of reduced-size lung transplants and
transplants in the pediatric population. 
We express our appreciation to Mr Anthony Herring, Ms
Sheila Hammond, and Dr Paul Davies for their invaluable
technical assistance. 
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Discussion
Dr Eric A. Rose (New York, NY). Will the growth factors
stimulate growth of malignant cells? Is this something that, if
it were to be used clinically in the setting of a pneumonecto-
my for lung cancer, would potentially cause recurrence of
disease? 
Dr Kaza. There have been various papers that have indi-
cated that EGF does indeed cause the transformation, but as
far as our animals were concerned, these were healthy ani-
mals. We did not see a transformation. However, we feel the
clinical application of this research is for the nonmalignant
patients, if any, for the patients with insufficient pulmonary
reserves, and for the modulation of growth in the lung trans-
plant patients, specifically, the pediatric patients. 
Dr Edward D. Verrier (Seattle, Wash). Could you notice
any functional differences in any of the animals?
Dr Kaza. We did not measure any functional parameters.
However, there have been classical studies that have shown
that oxygenation in compensatory lung growth equals that of
a bilateral lung ventilation. 
Dr Verrier. I am still concerned about the evidence that
you actually have cellular replication. There has got to be
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Dr Verrier. I think it is a fundamentally important question
and one that is not the easiest to get at experimentally. 
Dr Glen S. Van Arsdell (Toronto, Ontario, Canada). You
did extensive morphometric analysis of alveolar changes. Did
you also look at the vasculature that supplied it? 
Dr Kaza. No, we did not. This morphometric analysis that
is described by Dr Paul Davies is specifically used to quanti-
tate the various respiratory compartments in the lung and the
surface density of alveoli.
Dr Van Arsdell. Have you looked at the effects of EGF
without removal of the lung?
Dr Kaza. No, we have not.
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another way to get at showing that there is actually increased
alveolar replication. I recognize that you have tried to get at
that issue. It seems to me to be a critical issue that you actu-
ally are inducing—because that is a little unusual in adult tis-
sue, in the heart and other tissues, in order to actually induce
new cells to replicate. It is very difficult to do. Does anybody
else have that concern? 
Dr Kaza. Yes, we are actually looking at that. We are doing
immunostaining with BRDU to detect actual cell mitoses in
the pneumocytes, and we are actually using the technique in
the experiments that we are conducting right now, and we are
going to go back and look at this tissue as well. 
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